JP2020502059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502059A5 JP2020502059A5 JP2019526282A JP2019526282A JP2020502059A5 JP 2020502059 A5 JP2020502059 A5 JP 2020502059A5 JP 2019526282 A JP2019526282 A JP 2019526282A JP 2019526282 A JP2019526282 A JP 2019526282A JP 2020502059 A5 JP2020502059 A5 JP 2020502059A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- exon
- mutation
- pharmaceutical composition
- mutations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023067134A JP7685550B2 (ja) | 2016-11-17 | 2023-04-17 | Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423732P | 2016-11-17 | 2016-11-17 | |
| US62/423,732 | 2016-11-17 | ||
| US201662427692P | 2016-11-29 | 2016-11-29 | |
| US62/427,692 | 2016-11-29 | ||
| US201762572716P | 2017-10-16 | 2017-10-16 | |
| US62/572,716 | 2017-10-16 | ||
| PCT/US2017/062326 WO2018094225A1 (en) | 2016-11-17 | 2017-11-17 | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023067134A Division JP7685550B2 (ja) | 2016-11-17 | 2023-04-17 | Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502059A JP2020502059A (ja) | 2020-01-23 |
| JP2020502059A5 true JP2020502059A5 (https=) | 2021-01-07 |
| JP7265985B2 JP7265985B2 (ja) | 2023-04-27 |
Family
ID=62146809
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526282A Active JP7265985B2 (ja) | 2016-11-17 | 2017-11-17 | Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物 |
| JP2023067134A Active JP7685550B2 (ja) | 2016-11-17 | 2023-04-17 | Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023067134A Active JP7685550B2 (ja) | 2016-11-17 | 2023-04-17 | Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11446302B2 (https=) |
| EP (1) | EP3541832A4 (https=) |
| JP (2) | JP7265985B2 (https=) |
| KR (2) | KR102771603B1 (https=) |
| CN (2) | CN117599061A (https=) |
| AU (2) | AU2017363199B2 (https=) |
| BR (1) | BR112019010020A2 (https=) |
| CA (1) | CA3044432A1 (https=) |
| CL (1) | CL2019001353A1 (https=) |
| CO (1) | CO2019006218A2 (https=) |
| CU (1) | CU20190051A7 (https=) |
| EC (1) | ECSP19043254A (https=) |
| MA (1) | MA46852A (https=) |
| MX (1) | MX2019005834A (https=) |
| PE (1) | PE20191303A1 (https=) |
| PH (1) | PH12019501116A1 (https=) |
| TW (1) | TWI782931B (https=) |
| WO (1) | WO2018094225A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3679063A4 (en) * | 2017-09-08 | 2021-06-02 | The Regents of The University of Colorado, A Body Corporate | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF HER-CONTROLLED DRUG-RESISTANT CANCER |
| AU2019243738B2 (en) * | 2018-03-27 | 2024-05-30 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 19 mutations |
| CA3101657A1 (en) * | 2018-06-25 | 2020-01-02 | Spectrum Pharmaceuticals, Inc. | Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof |
| KR20210025064A (ko) * | 2018-06-25 | 2021-03-08 | 스펙트럼 파마슈티컬즈 인크 | 항-her1, her2 또는 her4 항체와 포지오티닙의 조합물 및 이의 사용 방법 |
| TW202012391A (zh) * | 2018-07-04 | 2020-04-01 | 日商第一三共股份有限公司 | 二芳基醚型喹唑啉衍生物 |
| BR112021004527A2 (pt) * | 2018-09-14 | 2021-06-08 | Spectrum Pharmaceuticals, Inc. | kits e métodos para tratamento contra câncer |
| CN113056272A (zh) * | 2018-09-21 | 2021-06-29 | 光谱医药公司 | 新的喹唑啉egfr抑制剂 |
| MX2021007554A (es) * | 2018-12-21 | 2021-08-11 | Univ Texas | Terapia de combinacion para el tratamiento de cancer. |
| BR112021016149A2 (pt) | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
| MX2021011925A (es) * | 2019-03-29 | 2021-11-03 | Univ Texas | Compuestos con actividad antitumoral contra celulas cancerigenas que portan inserciones del exon 21 del receptor 2 del factor de crecimiento epidermico humano. |
| MX2021011948A (es) * | 2019-03-29 | 2022-01-04 | Univ Texas | Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2. |
| CA3132816A1 (en) * | 2019-04-17 | 2020-10-22 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations |
| EP3956035A4 (en) * | 2019-04-17 | 2023-01-25 | Board of Regents, The University of Texas System | ANTI-CANCER LINKS WITH TYROSINE KINASE RESISTANT EGFR MUTATIONS |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| CA3148413A1 (en) * | 2019-08-23 | 2021-03-04 | Guru Reddy | Poziotinib combination with vegfr2 inhibitors and methods of use thereof |
| JP7777533B2 (ja) * | 2020-01-29 | 2025-11-28 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｎｒｇ１融合体を有するがんの治療のためのポジオチニブの使用 |
| WO2021155144A1 (en) * | 2020-01-29 | 2021-08-05 | Board Of Regents, The University Of Texas System | Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with nrg1 fusions |
| JP7783182B2 (ja) | 2020-02-12 | 2025-12-09 | ヤンセン バイオテツク，インコーポレーテツド | ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療 |
| CN111658650B (zh) * | 2020-05-28 | 2022-05-06 | 南通大学 | Mln4924在制备脉络膜新生血管治疗药物中的应用 |
| TW202211923A (zh) * | 2020-07-27 | 2022-04-01 | 美商光譜製藥公司 | 波奇替尼(poziotinib)於非小細胞肺癌之治療 |
| CN116194141A (zh) | 2020-08-25 | 2023-05-30 | 詹森生物科技公司 | 具有egfr突变的非小细胞肺癌的治疗 |
| KR20230094197A (ko) | 2020-09-23 | 2023-06-27 | 스코르피온 테라퓨틱스, 인코퍼레이티드 | 암 치료에 유용한 피롤로[3,2-c]피리딘-4-온 유도체들 |
| WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| TW202229282A (zh) | 2020-09-30 | 2022-08-01 | 美商史考皮恩治療有限公司 | 治療癌症之方法 |
| WO2022072632A1 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
| WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022165219A1 (en) * | 2021-01-29 | 2022-08-04 | Board Of Regents, The University Of Texas System | Methods of treating cancer with poziotinib |
| BR112023018278A2 (pt) | 2021-03-09 | 2023-10-31 | Janssen Biotech Inc | Tratamento de cânceres sem mutações de ativação de egfr |
| WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
| WO2023015149A1 (en) * | 2021-08-02 | 2023-02-09 | Spectrum Pharmaceuticals, Inc. | Treatment of non-small cell lung cancer with poziotinib |
| TW202342057A (zh) | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法 |
| WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| WO2024189544A1 (en) | 2023-03-13 | 2024-09-19 | Janssen Biotech, Inc. | Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies |
| CN121712773A (zh) | 2023-06-08 | 2026-03-20 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
| WO2025101809A1 (en) * | 2023-11-08 | 2025-05-15 | Fate Therapeutics, Inc. | Ipsc-derived t cells for solid tumor treatment |
| CN117587111A (zh) * | 2023-11-30 | 2024-02-23 | 苏州拓维生物技术有限公司 | 一种快速批量筛选化合物在激酶细胞系中活性的方法 |
| WO2026038160A1 (en) | 2024-08-13 | 2026-02-19 | Janssen Biotech, Inc. | Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies |
| CA3278557A1 (en) | 2024-08-13 | 2026-03-01 | Janssen Biotech, Inc. | Methods for reducing dermatologic adverse events in patients treated with egfr/met bispecific antibodies |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA190628A (en) | 1918-12-05 | 1919-05-27 | William J. Newton | Toggle socket |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| EP0665852A1 (en) | 1993-07-09 | 1995-08-09 | Amgen Boulder Inc. | Recombinant ctla4 polypeptides and methods for making the same |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US5869245A (en) | 1996-06-05 | 1999-02-09 | Fox Chase Cancer Center | Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands |
| US5844905A (en) | 1996-07-09 | 1998-12-01 | International Business Machines Corporation | Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US6723564B2 (en) | 1998-05-07 | 2004-04-20 | Sequenom, Inc. | IR MALDI mass spectrometry of nucleic acids using liquid matrices |
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| DE10042058A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| AU2003233451A1 (en) | 2002-03-26 | 2003-10-13 | Massachusetts Institute Of Technology | Targets, methods, and reagents for diagnosis and treatment of schizophrenia |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| ATE395346T1 (de) | 2003-09-16 | 2008-05-15 | Astrazeneca Ab | Chinazolinderivate als tyrosinkinaseinhibitoren |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| EP1845992A1 (de) | 2005-02-04 | 2007-10-24 | Boehringer Ingelheim International GmbH | Verwendung von tyrosinkinase-inhibitoren zur behandlung der chronischen rhinosinusitis |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| CN101516376A (zh) * | 2006-09-18 | 2009-08-26 | 贝林格尔.英格海姆国际有限公司 | 用于治疗携带egfr突变的癌症的方法 |
| AU2007299080B2 (en) * | 2006-09-18 | 2013-04-18 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US8137919B2 (en) * | 2008-04-10 | 2012-03-20 | Montefiore Medical Center | Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib |
| PE20100252A1 (es) | 2008-06-06 | 2010-04-12 | Boehringer Ingelheim Int | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| HUE030100T2 (en) | 2010-02-19 | 2017-04-28 | Xencor Inc | New CTLA4-IG immunoadhesins |
| KR101217526B1 (ko) | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
| KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
| EP2929350A4 (en) | 2012-12-04 | 2016-11-16 | Caris Mpi Inc | MOLECULAR PROFILING OF CANCER |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| AU2014296887A1 (en) | 2013-08-02 | 2016-01-28 | Aduro Biotech Holdings, Europe B.V. | Combining CD27 agonists and immune checkpoint inhibition for immune stimulation |
| BR112016003247B1 (pt) * | 2013-08-22 | 2022-05-10 | Taiho Pharmaceutical Co., Ltd | Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
-
2017
- 2017-11-17 KR KR1020237033201A patent/KR102771603B1/ko active Active
- 2017-11-17 CA CA3044432A patent/CA3044432A1/en active Pending
- 2017-11-17 MX MX2019005834A patent/MX2019005834A/es unknown
- 2017-11-17 WO PCT/US2017/062326 patent/WO2018094225A1/en not_active Ceased
- 2017-11-17 AU AU2017363199A patent/AU2017363199B2/en not_active Ceased
- 2017-11-17 KR KR1020197017346A patent/KR102585006B1/ko active Active
- 2017-11-17 BR BR112019010020A patent/BR112019010020A2/pt not_active Application Discontinuation
- 2017-11-17 US US16/461,992 patent/US11446302B2/en active Active
- 2017-11-17 EP EP17871141.2A patent/EP3541832A4/en active Pending
- 2017-11-17 PE PE2019001033A patent/PE20191303A1/es unknown
- 2017-11-17 CN CN202311334136.1A patent/CN117599061A/zh active Pending
- 2017-11-17 MA MA046852A patent/MA46852A/fr unknown
- 2017-11-17 JP JP2019526282A patent/JP7265985B2/ja active Active
- 2017-11-17 CU CU2019000051A patent/CU20190051A7/es unknown
- 2017-11-17 TW TW106139967A patent/TWI782931B/zh not_active IP Right Cessation
- 2017-11-17 CN CN201780083541.7A patent/CN110291104B/zh not_active Expired - Fee Related
-
2019
- 2019-05-17 PH PH12019501116A patent/PH12019501116A1/en unknown
- 2019-05-17 CL CL2019001353A patent/CL2019001353A1/es unknown
- 2019-06-14 CO CONC2019/0006218A patent/CO2019006218A2/es unknown
- 2019-06-17 EC ECSENADI201943254A patent/ECSP19043254A/es unknown
-
2022
- 2022-08-24 US US17/821,931 patent/US20230233563A1/en active Pending
-
2023
- 2023-04-17 JP JP2023067134A patent/JP7685550B2/ja active Active
- 2023-11-17 AU AU2023266384A patent/AU2023266384A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502059A5 (https=) | ||
| JP2022527788A5 (https=) | ||
| Zarkavelis et al. | Current and future biomarkers in colorectal cancer | |
| Mosrati et al. | TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma | |
| Kwon et al. | Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue | |
| CN102575295B (zh) | 可用于检测braf突变的方法、引物、探针和试剂盒 | |
| EP2505673B1 (en) | Polynucleotide primers for detecting PIK3CA mutations | |
| EP2580322B1 (en) | A mek 1 mutation conferring resistance to raf and mek inhibitors | |
| WO2013172933A1 (en) | Ethnic gene profile of genes involved in angiogenesis may predict regional bevacizumab efficacy difference in gastric cancer | |
| Huang et al. | Association of single nucleotide polymorphisms in IL-12 and IL-27 genes with colorectal cancer risk | |
| EP2227558A1 (en) | Method for classifying cancer patients as responder or non-responder to immunotherapy | |
| Clemens et al. | A modified Phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients. | |
| JP2022529016A5 (https=) | ||
| Gupta et al. | Association of TNF-α and TNFR1 promoters and 3′ UTR region of TNFR2 gene polymorphisms with genetic susceptibility to tobacco-related oral carcinoma in Asian Indians | |
| CN106148498A (zh) | Kras基因突变检测试剂盒及其应用 | |
| WO2011035538A1 (zh) | 用于定量检测egfr突变的试剂盒 | |
| JP2021519306A5 (https=) | ||
| RU2020134932A (ru) | Соединения с противоопухолевой активностью против раковых клеток, несущих мутации в экзоне 19her2 | |
| JP2022527499A5 (https=) | ||
| WO2011079524A1 (zh) | 用于定量检测k-ras突变的试剂盒 | |
| Verim et al. | Association between laryngeal squamous cell carcinoma and polymorphisms in tumor necrosis factor related apoptosis induce ligand (TRAIL), TRAIL receptor and sTRAIL levels | |
| Liu et al. | Quantitative assessment of AKAP12 promoter methylation in colorectal cancer using methylation-sensitive high resolution melting: Correlation with Duke's stage | |
| CN102796811A (zh) | 检测kras突变的试剂及方法 | |
| Kim et al. | PIK3CA mutations in hepatocellular carcinoma in Korea | |
| Kostakis et al. | Absence of hotspot mutations in exons 9 and 20 of the PIK3CA gene in human oral squamous cell carcinoma in the Greek population |